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Observed declines in drug resistance to nucleoside
reverse transcriptase inhibitors among persons recently
infected with HIV-1 in monitored subpopulations can be
interpreted as a positive sign and lead public health officials
to decrease efforts towards HIV prevention. By means of a
mathematical model, we identified 3 processes that can
account for the observed decline: increase in high-risk
behavior, decrease in proportion of acutely infected per-
sons whose conditions are treated, and change in treat-
ment efficacy. These processes, singly or in combination,
can lead to increases or decreases in disease and drug-
resistance prevalence in the general population. We dis-
cuss the most appropriate public health response under
each scenario and emphasize how further data collection
and analyses are required to more reliably evaluate the
observed time trends and the relative importance of forces
shaping the epidemic. Our study highlights how drug resist-
ance markers can be used as epidemiologic sentinels to
devise public health solutions. 
In recent years investigators have begun monitoring theHIV epidemic by reporting changes in the proportion of
newly infected persons who are carrying an HIV-1 drug-
resistant strain, i.e., the primary or acute resistant fraction.
Several studies report decreases in this primary resistant
fraction (1–7), including transient decreases (8–14).
Unfortunately, none of these studies included precise lon-
gitudinal data on the exact number and type of infected
persons or of the fraction of the total population that is
screened for acute infection or resistance, and as we show
here, making direct interpretations from data collected
from a subset of the population can lead to erroneous con-
clusions. Given the potentially serious clinical implica-
tions of drug resistance for HIV-infected persons, public
health officials and other authorities need to know whether
the decline in drug resistance among acutely infected per-
sons in the monitored subpopulations corresponds to a real
decline in drug resistance in the general population and
whether this effect is sustainable over time. The decline
might be interpreted as a positive sign caused, for example,
by less high-risk activity by HIV-positive persons infected
with a drug-resistant variant. This explanation could lead
public health officials to decrease their support for HIV
surveillance and prevention programs targeted at impeding
the spread of drug-resistant HIV strains such as drug-
resistance testing or adherence counseling. The amount of
resources that should be dedicated to drug resistance mon-
itoring and reporting is a controversial issue in light of the
recent isolation of a highly virulent multidrug-resistant
strain in New York City (15). Here we show how drug-
resistance data can offer not only clinical information
regarding appropriate treatment regimens for individual
patients, but also critical insights into an epidemic’s
course.  
Treatment History of HIV-1 and Its Impact 
on High-Risk Behavior
Different types of drugs have been developed to fight
HIV. Zidovudine (AZT), a nucleoside reverse transcriptase
inhibitor (NRTI), was first administered in 1987, and until
1995, monotherapy or dual therapy with NRTIs were the
only treatments available. The first protease inhibitor (PI),
saquinavir, was approved for treatment in 1995, followed
closely in 1996 by a nonnucleoside reverse transcriptase
inhibitor (NNRTI), nevirapine. These new drugs generated
a major change in the treatment strategy against HIV—
highly active antiretroviral therapy (HAART)—that coin-
cided with the start of the monitoring periods in several of
the studies mentioned above (1995–1996). With HAART,
at least 3 drugs are administered at the same time, which
substantially reduces viral load and, compared to results of
earlier regimens, increases the life expectancy of patients.
These advantages follow because the mutations necessary
to confer resistance to HAART are generated at a slower
rate and are lost more rapidly than those conferring resist-
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ance to monotherapy or dual therapy. Moreover, viral
strains resistant to HAART are not as efficient at complet-
ing their own life cycle (e.g., their replication rates are
lower), they may generate less illness and lower proportion
of deaths among infected persons, and the viral strains are
less likely to be transmitted to other persons. 
The primary resistance time trends observed for NRTIs
do not match those observed for the other 2 drug types. For
example, in North America some researchers report a
decrease in the proportion of persons recently infected
with a drug-sensitive HIV strain resistant to NRTIs; this
decrease is followed by an increase and subsequent
decrease (11–13). The pattern is particularly noticeable in
the study by Grant et al. (12), in which NRTI genotypic
resistance decreased from ≈30% in 1997 to 5% in 1999,
rose to 20% in 2000, and fell to 15% in 2001. Little et al.
also found this trend in primary resistance to NNRTIs (11).
These 2 studies (11,12) also documented a steady increase
in the proportion of persons newly infected with a virus
strain resistant to PIs. Here we focused on identifying the
likely forces responsible for the time trends exhibited by
viral strains resistant to NRTIs. We did so because their
time trends are expected to provide better insight into the
long-term dynamics of the epidemic than strains resistant
to PIs or NNRTIs, given that NRTIs have been adminis-
tered to more HIV-infected persons and for a longer peri-
od than the other 2 types of drugs (16,17). 
Treatment optimism after the initial successes of
HAART likely affected the subsequent dynamics of HIV
because these favorable treatment outcomes led some per-
sons to increase their high-risk behavior. Later it became
apparent that HAART does not completely eliminate HIV
from an infected person or impede its transmission.
Moreover, when HAART first became implemented, the
best strategy was believed to be “hit hard, hit early,”
because the medical community was trying to limit the
expansion of HIV within an infected person’s body and
ameliorate the gradual deterioration of the patient’s
immune system. However, HAART can have considerable
negative side effects, which affect the functioning of the
gastrointestinal system, renal system, pancreas, and liver
and produce changes in blood count, allergies, lactic acido-
sis, and other problems. As a result, treatment began to be
delayed to balance the following factors: 1) containing the
viral load, 2) minimizing the risk of drug-resistant mutants
developing by limiting the amount of treatment time, and
3) reducing negative side effects.
Modeling Drug Resistance in HIV
Empirical studies have shown that antiretroviral treat-
ment (ARV) produces substantial changes in the viral
dynamics at the within-host level that translate into sub-
stantial changes at the between-host level (8,18,19).
Mathematical and computational models permit us to cre-
ate simplified versions of complex realities that we can
manipulate to further our understanding of their dynamic
behavior. Consequently, numerous theoretical studies have
investigated the impact of drug therapy on HIV dynamics
at both levels (e.g., 20). Initial HIV treatment models (e.g.,
21–23) addressed how ARVs might affect the infectious-
ness of treated persons, and the spread of HIV and its dis-
ease-induced deaths. The magnitude of the public health
threat created by drug-resistant HIV strains was only rec-
ognized later. As a result, Zaric et al. presented a novel
model that showed that adhering to treatment regimens
would discourage the emergence of multidrug-resistant
HIV strains in heterogeneous populations (24). Blower et
al. developed a relatively simple but revealing determinis-
tic compartmental framework (25) that has served as the
reference point for most of the modeling studies subse-
quently done to investigate the effect of ARVs on disease
incidence and prevalence, drug-resistance transmission
and prevalence, AIDS death rate, and the potential to erad-
icate the HIV epidemic (26–31). Dangerfield et al. built a
detailed HAART treatment model that accounts for per-
sons in all 4 HIV stages, and the last is partitioned in early-
and late-stage AIDS (32). They investigated the effects of
HAART on HIV incidence and prevalence, assuming dif-
ferent average efficacious periods and assimilation times
for HAART, different infectivity probabilities when
receiving HAART, and different increases in the mean
number of sexual partners. 
Blower and Volberding reviewed mathematical studies
used to understand the dynamics of a drug-resistant HIV
epidemic, predict the incidence and prevalence of drug-
resistant HIV strains, evaluate cost-benefit strategies, and
assess the impact of public health policies (33). The gener-
al approach to these studies had been to construct a
descriptive simplification of the epidemic by identifying
critical categories and processes and to use this structure to
make predictions, given a set of assumptions regarding the
parameter values. In this regard, several studies have char-
acterized the epidemic’s trends as monotonic, including
the fraction of new HIV infections that are drug resistant
(e.g., 16,25,28,34). Goudsmit et al. conducted an analysis
in which including changes in treatment rates explained
the nonmonotonic trends of zidovudine resistance
observed in a cohort of newly infected homosexual men
enrolled in the Amsterdam Cohort Study (1). 
In our previous study (35), we extended the basic mod-
eling framework detailed in (25) to incorporate additional
complexity, including 2–3 separate categories of acutely
infected persons, depending on whether a person was
infected with a drug-sensitive HIV strain, a strain resistant
to monotherapy, or a strain resistant to triple-drug therapy.
In doing so, we were able to distinguish among acutely
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infected persons, who are clinically and epidemiologically
distinct from uninfected and chronically infected persons
(e.g., we can consider them to engage more frequently in
high-risk behavior (2) than chronically infected persons).
We also counted these categories separately and tracked
their temporal trends and better channeled the different
categories through the model, according to the different
processes acting on them (such as a decrease in the propor-
tion of persons receiving treatment among those recently
infected, an effect that did not occur in persons in the
chronic phase). We also created 10 subcategories in the
chronically infected stage to more accurately represent the
progression of persons from the acute stage of infection to
AIDS (35). Moreover, because our intent was to explain
observed trends rather than to make future predictions, we
adopted a specific approach that consisted in altering indi-
vidually the value of each parameter during a given simu-
lation (as was done in [1] with treatment rates of all
persons), rather than running simulations with a set of
fixed parameters and comparing outcomes across runs. 
Primary Resistant Fraction
The most direct explanation for the decrease in the
observed proportion of newly infected persons infected
with NRTI-resistant HIV-1 strains is that resistance to
NRTIs in the recently HIV-infected population is declin-
ing. Unfortunately, the data need to be further evaluated
because the HIV infection status of every person in the
general population has not been monitored. We therefore
do not have absolute numbers for these time trends, but
only the relative numbers obtained from monitored sub-
populations, which consist of consenting persons enrolled
in research programs at specific locations. To be eligible to
participate in these programs, patients had to display
symptoms typical of an acute HIV seroconversion syn-
drome or have recently engaged in risky activities that
could have placed them at risk of contracting HIV.
Accordingly, what has decreased is the fraction of drug-
resistant carriers among the pool of recently infected HIV
patients who are willing to participate in particular
research programs and attend clinics involved in these
studies. The time trends exhibited by the variable repre-
senting the actual counts of all the newly infected persons
who are carriers for a resistant strain in the general popu-
lation may or may not be a direct match to those of the
monitored subpopulations.
These points are best illustrated by considering the frac-
tion of recently infected persons who are carriers of a drug-
resistant strain (primary resistant fraction, FR), defined
mathematically as
,
where S is the number of persons initially infected with a
drug-sensitive strain, and R is the number of persons ini-
tially infected with a drug-resistant strain. This fraction
may decrease because R decreases (fewer newly infected
persons have a strain that is drug resistant), or because S
increases (more newly infected persons carry drug-sensi-
tive strains). If both S and R increase or decrease by the
same proportion, FR remains unchanged. As explained
below, the benefit of using this variable’s time trends to
further our understanding of the past, present, and future of
the HIV epidemic is that underlying alterations in the rela-
tive values of drug-sensitive and drug-resistant strains may
arise from a variety of mechanisms with critically different
epidemiologic outcomes. 
To determine which processes could have caused the
observed decrease in FR, we built a mathematical model of
HIV transmission (Figure 1); a more mathematically
detailed explanation of our analysis can be found in our
previous study (35). We then simulated the epidemic using
this model and varied each of the parameters shown in
Figure 1 (e.g., the average number of high-risk contacts in
1 year, the likelihood of transmitting HIV given a high-risk
contact, the fraction of persons with acute or chronic HIV
Drug-resistant HIV Strains as Epidemiologic Sentinels
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Figure 1. Flow chart of the different categories and flows consid-
ered in our model system. For simplicity, we considered 1 type of
treatment when analyzing the effects of an increase in high-risk
behavior and treatment delay. When considering the effects of
overall change in treatment strategy, all categories and flows were
included in the analysis. Abbreviations: m, mortality (composed of
background deaths for all categories, and for persons in the chron-
ic phase of infection, HIV-related deaths are included); Rx, treat-
ment; R, resistance; M, monotherapy; H, highly active
antiretroviral therapy (HAART). Color code for the categories’
encircling ovals: black (uninfected); purple (wild type); blue
(monotherapy resistant strain); green (HAART-resistant strain).
Background code of oval categories: no fill (untreated); tan
(monotherapy); gray (HAART). Code for the categories’ encircling
ovals: single, no staging (uninfected and acutely infected); double,
staged categories (persons in the chronic phase).
infection that are placed on treatment each year, the likeli-
hood of generating or losing drug resistance in 1 year).
Once we determined which processes can cause a decrease
in the acute fraction infected with a drug-resistant strain, we
evaluated whether the process had occurred in industrial-
ized countries in recent years. If so, we could consider the
process as a potential contributor to the observed trends. As
a result, we identified 3 independent processes that caused
a decrease in FR and were consistent with the history of the
HIV-1 epidemic in industrialized countries from 1995 to
2001: 1) overall increase in risky behavior, 2) decrease in
the fraction of individuals in the acute phase who are placed
on treatment, and 3) increase in the efficacy of treatment.
Goudsmit et al. also found that discontinuation of
monotherapy with zidovudine in 1996 explained the
observed drop in zidovudine resistance in patients newly
infected with HIV in the Amsterdam Cohort Study (1). 
Figure 2A illustrates the outcomes of running the model
given our manipulation of the parameter values character-
izing these 3 processes. We obtained the same qualitative
patterns across all reasonable combinations of parameter
values. When high-risk behavior increases, the drug-sensi-
tive strain has an initial advantage over the drug-resistant
strain because of its higher transmission rate, and it
increases to its equilibrium prevalence value at a faster
pace than the drug-resistant strain. This increase causes a
temporary decrease in FR (solid trajectory, Figure 2A). The
decrease is only temporary because the relative equilibri-
um prevalence value of the strains is independent of the
risky behavior rate, and the relative prevalence value
among acute FR returns to its original value before the per-
turbation (35). If fewer persons are treated, fewer patients
will be generating and transmitting drug-resistant strains
(dashed trajectory, Figure 2A). The change in treatment
efficacy also leads to a decrease in FR because drug-resist-
ant strains are harder to generate and are less likely to be
transmitted under treatment with HAART than under
monotherapy with AZT (dotted trajectory, Figure 2A).
Figure 2A shows that the long-term behavior of the pri-
mary resistant fraction is substantially different under the
3 scenarios, even though it initially decreases for all 3. 
Course of the HIV Epidemic 
How do these 3 processes (increase in high-risk behav-
ior, treatment delay, and greater treatment efficacy) impact
the course of the HIV epidemic? Are these effects compa-
rable or are they sufficiently different such that the policy
implications will vary according to which one we interpret
to be the leading cause for the observed decline? To
address these questions, we determined the short- and
long-term changes induced by these processes on 2 vari-
ables of critical public health importance for which we do
not have reliable measurements: prevalence of disease
PERSPECTIVE
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Figure 2. Time trends for A) proportion of persons in the acute
phase infected with a resistant viral strain, B) disease prevalence
in the population, and C) resistance prevalence in the population.
At time t = 10 years, we introduce a 1) increase in high-risk behav-
ior from 2 to 4 contacts/person/year, or 2) decrease in the yearly
fraction of acutely infected persons on treatment from 0.4 to 0.1,
or 3) increase in treatment efficacy from monotherapy with zidovu-
dine (AZT) to highly active antiretroviral therapy (HAART). All other
parameter values and conditions are as reported by Sánchez et al.
(35). At t = 0, there is 1 infected person in a population of 100,000.
For the first 2 processes, we let the simulations reach equilibrium
and then introduced the change. The graphs show the trajectories
starting at equilibrium and the changes occurring after 10 years.
The third process reconstructs San Francisco's historical time
frame for the treatment regimen change. Now the epidemic runs
without treatment for 30 years, monotherapy with AZT follows for
10 years, and HAART begins at t = 40. To facilitate the compari-
son with the first 2 processes, we graphed the dynamics of the
treatment change from the moment AZT was introduced.
(i.e., overall fraction of persons infected with HIV in the
general population) and prevalence of drug resistance (i.e.,
overall fraction of persons infected with a drug-resistant
HIV strain in the general population). By doing so, we use
time trend changes in the relative prevalence values of 2
viral strains (i.e., the fraction FR defined above) to make
inferences about changes in the absolute values of disease
and resistance prevalence in the population (i.e., actual
counts of infected persons and carriers of drug-resistant
infections in the general population). Figures 2B and 2C
show that the 3 factors we identified as causing a decrease
in the primary resistant fraction are predicted to force dif-
ferent and permanent, long-term changes in disease and
drug-resistance prevalence. A synopsis of our findings is
provided in the Table. 
Policy Implications and Comparison 
with the Data
Our results demonstrate how a decrease in the fraction
of persons recently infected with a drug-resistant HIV
strain can occur not only when the epidemiologic condi-
tions improve (i.e., disease and drug-resistance prevalence
in the population decrease), but also when the epidemic
worsens (i.e., disease and drug-resistance prevalence
increase). The 3 processes that can generate the decrease in
primary resistance are not mutually exclusive, and proba-
bly all have contributed to the observed time course of FR.
The challenge now is to identify which one has had the
greatest effect on the recent trends of disease and drug-
resistance prevalence in the HIV-1 epidemic.
If an increase in high-risk behavior has dominated
HIV-1 epidemiology since the onset of HAART, then the
decrease in primary resistance, counter to intuition, signals
a worsening of the epidemic: a greater number of persons
may have become infected, and a greater number of per-
sons may be infected with a viral strain resistant to drug
therapy. Other studies have obtained similar conclusions
(e.g., 28,29,31,32). If this is the case, the public health
response to the decrease in drug-resistance levels among
the acutely infected should be to expand programs aimed
at reducing high-risk behavior. 
Determining the most appropriate public health
response is difficult if a decrease in the fraction of acutely
ill persons receiving treatment is the main driving force of
the HIV epidemic. Under this scenario, the indications for
treating acutely infected persons may need to be modified
by taking into account the potential balance between an
increased number of infected persons as opposed to a
decreased number of carriers of drug-resistant infections.
Cost-benefit analyses of this nature are an intrinsic part of
public health policy (33). In any case, we do not expect
this process to be the main driving force responsible for
recent trends in disease and drug resistance in the HIV-1
epidemic because the number of persons in the acute phase
of HIV infection is much smaller than that in the chronic
phase (1), and a large proportion of chronically infected
patients received HAART at the beginning of the study
period (36). Moreover, new treatment regimens, such as
structured treatment interruptions and drug holidays, may
have affected recent drug-resistance trends (36).
The most favorable outcome occurs if the increase in
treatment efficacy brought about with HAART is the most
important process determining recent HIV-1 trends. Now
both the prevalence of the disease and of drug resistance in
the population are decreasing, and therefore the decline in
drug-resistance prevalence among the acutely infected is a
positive sign (25,26,32). Results under this scenario under-
score the importance of public health interventions direct-
ed toward increasing the number of persons receiving
treatment (we must keep in mind that these results assume
that the fraction of persons treated remains constant).
However, the uncertainty in the parameters does not
allow us to readily distinguish between the 3 likely scenar-
ios. Moreover, we cannot be sure that the trends observed
correspond to a real decrease in FR, or are simply fluctua-
tions due to stochastic or sampling phenomena around a
monotonically increasing time trend (11,18,25,34,37–39).
Little et al. and Grant et al. report trends consistent with
the first scenario: the decrease in the fraction of persons
infected with an NRTI-resistant strain is followed by an
increase and subsequent decrease (11–13). Several authors
report biphasic patterns of alternating trends
(1,2,5,9,10,14), which are not necessarily correlated with
an increase in non-B subtypes (8). Other studies report
overall increasing (38), stable (40), and decreasing
(3,4,6,7) trends in the proportion of persons recently
infected with an NRTI drug-resistant HIV-1 strain. These
studies, together with our results, highlight why disease
surveillance must be increased, with additional data collec-
tion and analyses, to fully understand the present and
future course of the HIV epidemic. In this regard, mathe-
matical modeling can provide a crucial tool for the correct
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interpretation of epidemiologic data by identifying the
processes responsible for generating observed time trends
and characterizing their potential implications for public
health programs. 
Conclusion
Our mathematical analysis shows that the observed
time trends of measurable quantities from particular sub-
groups of infected persons (such as primary drug resistance
in monitored subpopulations) can correspond to different
and unexpected time trends of variables of critical public
health interest that are not measured directly in the general
population. On the other hand, with the appropriate analy-
ses, information on drug resistant strains can be used not
only to guide treatment in individual patients, but also as
epidemiologic sentinels to help devise public health solu-
tions. Because changes in the relative value of 2 strains that
vary in any of their life history traits (such as their ability
to be transmitted, to be suppressed when in the presence of
drug therapies, or to lose mutations that confer drug resist-
ance) can show information on an epidemic’s trends, the
reasoning and methods we used in this study can be
applied equally well to understand the epidemiology of any
genetically variable microbe. 
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